Development of Secondary Cancers in Pre- vs Post-ICI Eligibility Periods for Metastatic Cancers

This cohort study investigates incidence of secondary primary cancers before vs after approval of immune checkpoint inhibitors (ICIs) among patients with metastatic cancers.

Corresponding Author: Michael L. Chen, MD, Center for Digital Health, Stanford University School of Medicine, 269 Campus Dr, CCSR 4325, Stanford, CA 94305 (mchen20@stanford.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.